tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NUVL Stock Latest News

Carvana initiated, AT&T upgraded: Wall Street’s top analyst calls
The FlyCarvana initiated, AT&T upgraded: Wall Street’s top analyst calls
3d ago
T
AN
Canaccord starts ‘best-in-class’ Nuvalent with Buy rating
PremiumThe Fly
Canaccord starts ‘best-in-class’ Nuvalent with Buy rating
3d ago
NUVL
Nuvalent initiated with a Buy at Canaccord
PremiumThe Fly
Nuvalent initiated with a Buy at Canaccord
3d ago
NUVL
Nuvalent price target raised to $120 from $105 at Goldman Sachs
PremiumThe Fly
Nuvalent price target raised to $120 from $105 at Goldman Sachs
15d ago
NUVL
Nuvalent price target raised to $132 from $114 at UBS
PremiumThe Fly
Nuvalent price target raised to $132 from $114 at UBS
15d ago
NUVL
Nuvalent’s Promising Drug Pipeline and Strong Financials Make It a Buy
PremiumRatingsNuvalent’s Promising Drug Pipeline and Strong Financials Make It a Buy
15d ago
NUVL
Nuvalent price target raised to $112 from $100 at Barclays
Premium
The Fly
Nuvalent price target raised to $112 from $100 at Barclays
15d ago
NUVL
Nuvalent, Inc. Reports Q3 2025 Progress and Financials
Premium
Company Announcements
Nuvalent, Inc. Reports Q3 2025 Progress and Financials
15d ago
NUVL
Nuvalent’s Strong Financial Position and Strategic Progress Drive Buy Rating
PremiumRatings
Nuvalent’s Strong Financial Position and Strategic Progress Drive Buy Rating
16d ago
NUVL
Nuvalent reports Q3 EPS ($1.70), consensus ($1.32)
PremiumThe Fly
Nuvalent reports Q3 EPS ($1.70), consensus ($1.32)
16d ago
NUVL
Nuvalent’s Zidesamtinib Study: A Potential Game-Changer in Cancer Treatment
PremiumCompany Announcements
Nuvalent’s Zidesamtinib Study: A Potential Game-Changer in Cancer Treatment
19d ago
NUVL
Nuvalent’s Promising Phase 3 Study: A Potential Game-Changer in NSCLC Treatment
PremiumCompany Announcements
Nuvalent’s Promising Phase 3 Study: A Potential Game-Changer in NSCLC Treatment
19d ago
NUVL
Nuvalent’s NVL-330 Study: A Potential Game-Changer for HER2-Altered NSCLC
PremiumCompany AnnouncementsNuvalent’s NVL-330 Study: A Potential Game-Changer for HER2-Altered NSCLC
19d ago
NUVL
Nuvalent’s ALKOVE-1 Study: A Potential Game-Changer in ALK-Positive Cancer Treatment
Premium
Company Announcements
Nuvalent’s ALKOVE-1 Study: A Potential Game-Changer in ALK-Positive Cancer Treatment
19d ago
NUVL
3 Best Stocks to Buy Now, 10/27/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 10/27/2025, According to Top Analysts
19d ago
WAY
CRNX
Nuvalent price target raised to $128 from $112 at Piper Sandler
PremiumThe Fly
Nuvalent price target raised to $128 from $112 at Piper Sandler
19d ago
NUVL
Nuvalent presents preliminary data for neladalkib from ALKOVE-1 Phase 1/2 trial
PremiumThe Fly
Nuvalent presents preliminary data for neladalkib from ALKOVE-1 Phase 1/2 trial
27d ago
NUVL
Nuvalent resumed with a Buy at Stifel
PremiumThe Fly
Nuvalent resumed with a Buy at Stifel
1M ago
NUVL
Cantor starts Nuvalent at Overweight, sees 60% potential upside
PremiumThe Fly
Cantor starts Nuvalent at Overweight, sees 60% potential upside
1M ago
NUVL
Nuvalent initiated with an Overweight at Cantor Fitzgerald
PremiumThe FlyNuvalent initiated with an Overweight at Cantor Fitzgerald
1M ago
NUVL
Nuvalent’s Promising Oncology Prospects: A Buy Rating Driven by ALKOVE-1 Trial and Market Potential
Premium
Ratings
Nuvalent’s Promising Oncology Prospects: A Buy Rating Driven by ALKOVE-1 Trial and Market Potential
1M ago
NUVL
Nuvalent’s Promising Prospects: Buy Rating Backed by Pivotal Drug Readout and Strong Pipeline Potential
Premium
Ratings
Nuvalent’s Promising Prospects: Buy Rating Backed by Pivotal Drug Readout and Strong Pipeline Potential
1M ago
NUVL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >